Prostate Cancer Clinical Trials in Washington D.C., District of Columbia

8 studies are recruiting for prostate cancer in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The GW Medical Faculty Associates ( Site 0057), Washington D.C., District of Columbia

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

2. MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer

   The goal of this clinical trial is to determine the safety of stereotactic body radiation therapy (SBRT) microboost technique in patients with low to intermediate risk prostate cancer. The main question it aims to answer is: Is microboost SBRT with whole gland de-escalation both safe and effective …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C., District of Columbia

   Run by

   Georgetown University

   See if you can join NCT07644598 on ClinicalTrials.gov

3. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Johns Hopkins University, Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

4. Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

   The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as …

   Stage

   Phase 4

   Ages

   18 to 100

   Site

   VA Medical Center, Washington D.C., District of Columbia

   Locations

   54 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT05803941 on ClinicalTrials.gov

5. Clinical Trial of Approaches to Prostate Cancer Surgery

   This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatectomy. The investigators hypothesize that pelvic fascia-sparing radical prostatectomy will have simil…

   Stage

   Not phased

   Ages

   40 to 80

   Site

   Georgetown University, Washington D.C., District of Columbia

   Locations

   9 in total

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT05155501 on ClinicalTrials.gov

6. Castrate Resistant Prostate Cancer Enhertu Therapy

   Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Washington DC VAMC, Washington D.C., District of Columbia

   Run by

   Washington D.C. Veterans Affairs Medical Center

   See if you can join NCT06610825 on ClinicalTrials.gov

7. Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

   This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic pros…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Washington DC VA Medical Center, Washington, DC, Washington D.C., District of Columbia

   Locations

   20 in total

   Run by

   VA Office of Research and Development

   See if you can join NCT04787744 on ClinicalTrials.gov

8. Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

   The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer. …

   Stage

   Not phased

   Ages

   40 to 69

   Site

   Howard University Hospital, Washington D.C., District of Columbia

   Locations

   5 in total

   Run by

   Adam S. Kibel, MD

   See if you can join NCT06398639 on ClinicalTrials.gov